Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

49.54 2.19 +4.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Book value per share

Alert me on Book value per share

Septerna, Inc.'s book value per share at the end of fiscal 2025 was 8.6×, down 79.7% from 42.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 8.6×. Septerna, Inc. ranks 90th of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 8.6× (79.68%)
FY2024 42.5× —
FY2023 −19.9× —

Quarterly newest first

Period Book value per share Change
Jun 2026 8.6× 1.55%
Mar 2026 8.5× (2.02%)
Dec 2025 8.6× (1.56%)
Sep 2025 8.8× 2.55%
7 more quarters

Book value per share against peers

Company Book value per share
PVLA Palvella Therapeutics, Inc. compare 15.1×
SEPN Septerna, Inc. 8.6×
VCEL Vericel Corporation compare 7.5×
VERA Vera Therapeutics, Inc. compare 5.7×
AUPH Aurinia Pharmaceuticals Inc compare 4.9×
IMNM Immunome, Inc. compare 4.6×
ZYME Zymeworks Inc. compare 1.1×
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 0.0×
BHVN Biohaven Ltd. compare −0.7×

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on SEPN